David Sims
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Sims has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- David R. Patton
Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD
32 shared publications - Lyndsay N. Harris
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
32 shared publications - Peter J. O'Dwyer
University of Pennsylvania, Philadelphia, PA
32 shared publications - Stanley R. Hamilton
City of Hope National Medical Center, Duarte, CA
32 shared publications - Catherine J. Wu
Dana-Farber Cancer Institute
31 shared publications - Christina Coppola
Center for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
31 shared publications
Latest Publications
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (16) , OF1-OF14
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Purpose: NCI selected a network of Clinical Laboratory Improvement Amendments–certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms. Experimental Design: Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed for single-nucleotide variant, insertion and deletion, and copy-number variant classes. Results: We observed high concordance in variant detection between CL and DL for single-nucleotide variants and insertions and deletions [average positive agreement (APA) > 95.4% for all pairwise comparisons] but lower concordance for variant reporting after analysis pipeline filtering. We observed much higher agreement between CL and assays using amplification as the target enrichment method (84.2% < APA ≤ 95.7%, average APA = 88.7%) than other assays using hybridization capture (69.7% < APA ≤ 93.8%, average APA = 77.4%) due to blacklisting of actionable variants in low complexity regions. For copy-number variant reporting, we observed high agreement (APA > 82%) except between CL and two assays (APA = 76.9% and 71.4%) due to differences in estimation of copy numbers. Notably, for all variants, differences in variant interpretation also contributed to reporting discrepancies. Conclusions: This study indicates that different NGS tumor profiling tests currently in widespread clinical use achieve high concordance between assays in variant detection. For variant reporting, observed discrepancies are mainly introduced during the bioinformatic analysis.
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (16) , OF1-OF14
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Purpose: NCI selected a network of Clinical Laboratory Improvement Amendments–certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms. Experimental Design: Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed for single-nucleotide variant, insertion and deletion, and copy-number variant classes. Results: We observed high concordance in variant detection between CL and DL for single-nucleotide variants and insertions and deletions [average positive agreement (APA) > 95.4% for all pairwise comparisons] but lower concordance for variant reporting after analysis pipeline filtering. We observed much higher agreement between CL and assays using amplification as the target enrichment method (84.2% < APA ≤ 95.7%, average APA = 88.7%) than other assays using hybridization capture (69.7% < APA ≤ 93.8%, average APA = 77.4%) due to blacklisting of actionable variants in low complexity regions. For copy-number variant reporting, we observed high agreement (APA > 82%) except between CL and two assays (APA = 76.9% and 71.4%) due to differences in estimation of copy numbers. Notably, for all variants, differences in variant interpretation also contributed to reporting discrepancies. Conclusions: This study indicates that different NGS tumor profiling tests currently in widespread clinical use achieve high concordance between assays in variant detection. For variant reporting, observed discrepancies are mainly introduced during the bioinformatic analysis.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Summary of evidence evaluating potential predictive biomarkers of response to immune checkpoint blockade in patients with MSI-H non-colorectal cancer tumors
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Summary of evidence evaluating potential predictive biomarkers of response to immune checkpoint blockade in patients with MSI-H non-colorectal cancer tumors
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
EnrichR results of top mutant genes from MutSig2CV
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
EnrichR results of top mutant genes from MutSig2CV
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Baseline characteristics for patients with (in) or without (out) molecular data
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Baseline characteristics for patients with (in) or without (out) molecular data
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Subject MSI and MANTIS score correlation
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Subject MSI and MANTIS score correlation
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Representativeness of study participants
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Representativeness of study participants